Nimotop (Nimodipine)

Nimodipine, the active ingredient in Nimotop, is a calcium channel blocker presented as a sterile solution for intracisternal and intravenous use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients. GNH USA supplies Nimotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Nimotop is a cerebral vasodilator indicated for conditions involving post‑hemorrhagic cerebral vasospasm. - Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits. - Aneurysmal subarachnoid hemorrhage: helps maintain cerebral perfusion during the critical vasospasm period. - Neurosurgical patients at risk of vasospasm: supports cerebral blood flow to limit secondary brain injury.

Nimotop may cause a range of adverse reactions, most of which are dose‑related and reversible.

Common Side Effects: - Hypotension: transient drop in blood pressure. - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Flushing: warm sensation with skin reddening. - Dizziness: sensation of light‑headedness. - Tachycardia: increased heart rate.

Serious or Rare Side Effects: - Severe hypotension: may require medical intervention. - Myocardial infarction: rare cardiac event. - Hepatic dysfunction: elevated liver enzymes. - Allergic reaction: rash, pruritus, or anaphylaxis. - Stevens‑Johnson syndrome: severe skin eruption. - Seizures: uncommon neurologic event.

When using Nimotop, clinicians should observe specific safety measures. - Monitor blood pressure: watch for symptomatic hypotension. - Assess liver function: adjust use if hepatic impairment is present. - Avoid concurrent vasodilators: risk of additive blood pressure lowering. - Use caution in elderly patients: increased sensitivity to hemodynamic changes. - Store at ambient temperature: keep in original container, protect from moisture and light.

Nimotop can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Other calcium channel blockers: additive vasodilation may cause profound hypotension. - Potent CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase nimodipine plasma concentrations. - Nitrates: combined effect can lead to severe blood pressure drops.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may enhance bradycardia and hypotension. - Diuretics: can affect electrolyte balance and blood pressure. - Other antihypertensives: may require dose adjustment to maintain target blood pressure.